Evidence map›Paper›PMID 39654607›Full record

ArticleRespiratory medicine case reports2024

Interstitial lung disease in a patient with anti-eIF2B antibodies-positive systemic sclerosis: A case report and literature review.

Naoya Aoshiba, Kazutoshi Toriyama, Shohei Yamashita, Nao Shioiri, Yuko Iwata, Tomonori Uruma, Shinji Abe, Kenji Tsushima

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Naoya AoshibaDepartment of Respiratory Medicine, Tokyo Medical University Hachioji Medical Center, 1163, Tatemachi, Hachioji-shi, Tokyo, Japan.
Kazutoshi ToriyamaDepartment of Respiratory Medicine, Tokyo Medical University Hachioji Medical Center, 1163, Tatemachi, Hachioji-shi, Tokyo, Japan.
Shohei YamashitaDepartment of Rheumatology, Tokyo Medical University Hachioji Medical Center, 1163, Tatemachi, Hachioji-shi, Tokyo, Japan.
Nao ShioiriDepartment of Respiratory Medicine, Tokyo Medical University Hachioji Medical Center, 1163, Tatemachi, Hachioji-shi, Tokyo, Japan.
Yuko IwataDepartment of Respiratory Medicine, Tokyo Medical University Hachioji Medical Center, 1163, Tatemachi, Hachioji-shi, Tokyo, Japan.
Tomonori UrumaDepartment of Respiratory Medicine, Tokyo Medical University Hachioji Medical Center, 1163, Tatemachi, Hachioji-shi, Tokyo, Japan.
Shinji AbeDepartment of Respiratory Medicine, Tokyo Medical University Hospital, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan.
Kenji TsushimaDepartment of Respiratory Medicine, Tokyo Medical University Hachioji Medical Center, 1163, Tatemachi, Hachioji-shi, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the case of a 76-year-old male patient with systemic sclerosis positive for anti-eukaryotic initiation factor 2B (eIF2B) antibodies. He presented to our hospital with dyspnea on exertion and, following a comprehensive physical examination, was diagnosed with interstitial lung disease associated with systemic sclerosis. Furthermore, systemic sclerosis was positive for the anti-eIF2B antibody. The presence of anti-eIF2B antibodies in systemic sclerosis is very rare, occurring in only 1-2.5 % of cases and seldom reported. Similar to our case, systemic sclerosis with positive anti-eIF2B antibodies has been reported to be more likely to be complicated by interstitial lung disease. Herein, we discuss our case in detail and summarize the previous findings.

Indexed as

anti-eIF2B antibodiesInterstitial lung diseaseSystemic sclerosis

Identifiers

PMID39654607
PMCPMC11626813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.